Thank you for using version 2025.4.1104.462 of Telerik Document Processing Libraries. Access to the latest updates and support requires a license. Learn more in the documentation below. Learn more about Telerik Document Processing Libraries licensing https://docs.telerik.com/devtools/document-processing/distribution-and-licensing/license-key

MAYO CLINIC LABORATORIES

Test Definition: PGKC

Phosphoglycerate Kinase Enzyme Activity, Blood

Overview

Useful For

Evaluation of individuals with Coombs-negative nonspherocytic hemolytic anemia, especially if X-linked inheritance pattern, as a part of a profile

Evaluation of individuals with myopathic or neurologic symptoms

Method Name

Only orderable as part of a profile. For more information see:
-HAEV1 / Hemolytic Anemia Evaluation, Blood
-EEEV1 / Red Blood Cell (RBC) Enzyme Evaluation, Blood

Kinetic Spectrophotometry (KS)

NY State Available

Yes

Specimen

Specimen Type

Whole Blood ACD-B

Specimen Required

Only orderable as part of a profile. For more information see:
-HAEV1 / Hemolytic Anemia Evaluation, Blood
-EEEV1 / Red Blood Cell (RBC) Enzyme Evaluation, Blood

Reject Due To

Gross hemolysis	Reject
Fully clotted	Reject

Specimen Stability Information

Specimen Type	Temperature	Time	Special Container
Whole Blood ACD-B	Refrigerated	20 days	

Clinical & Interpretive

Clinical Information

Phosphoglycerate kinase (PGK) is an enzyme that converts 1,3-diphosphoglycerate into 3-phosphoglyceric acid), during glycolysis, representing one of the adenosine triphosphate-generating steps. PGK deficiency (OMIM 300653) is an X-linked disorder with a variable clinical phenotype. Manifestations include hemolytic anemia, myopathy/rhabdomyolysis, or neurologic impairment. Patients can have 1 or 2 systems affected but rarely have all 3. Clinical severity may not correlate with enzyme activity and female heterozygous individuals may possibly be mildly affected.

Reference Values

Only orderable as part of a profile. For more information see:
-HAEV1 / Hemolytic Anemia Evaluation
-EEEV1 / Red Blood Cell (RBC) Enzyme Evaluation

> or =12 months: 142-232 U/g Hb
Reference values have not been established for patients younger than 12 months.

Interpretation

In phosphoglycerate kinase deficiency, red blood cell activity levels have been reported ranging from 1% to 49% of mean normal; however, affected patients more typically have values less than 20% of normal mean.(1)

Cautions

Recent transfusion may mask the patient’s intrinsic enzyme activity and cause unreliable results.

Clinical Reference

1. Chiarelli LR, Morera SM, Bianchi P, et al. Molecular insights on pathogenic effects of mutations causing phosphoglycerate kinase deficiency. PLoS One. 2012;7(2):e32065. doi:10.1371/journal.pone.0032065
2. Valentine WN, Hsieh HS, Paglia DE, et al. Hereditary hemolytic anemia associated with phosphoglycerate kinase deficiency in erythrocytes and leukocytes: a probable X-chromosome-linked syndrome. New Eng J Med. 1969;280(10):528-534
3. Beutler E. PGK deficiency. Br J Haematol. 2007;136(1):3-11
4. Koralkova P, van Solinge WW, van Wijk R. Rare hereditary red blood cell enzymopathies associated with hemolytic anemia-pathophysiology, clinical aspects and laboratory diagnosis. Int J Lab Hematol. 2014;36:388-397
5. Echaniz-Laguna A, Nadjar Y, Behin A, et al. Phosphoglycerate kinase deficiency: A nationwide multicenter retrospective study. J Inherit Metab Dis. 2019;42(5):803-808

Performance

Method Description

Phosphoglycerate kinase (PGK) catalyzes the phosphorylation of adenosine diphosphate (ADP) to adenosine

triphosphate (ATP) by conversion of 1,3-diphosphoglycerate (1,3-DPG) to 3,phosphoglyceric acid. In this assay, the reaction is driven in the reverse direction. The formation of 1,3-DPG is then measured through the glyceraldehyde phosphate dehydrogenase reaction as 1,3-DPG is converted to glyceraldehyde-3-phosphate resulting in the oxidation of 1,4-dihydronicotinamide adenine dinucleotide (NADH) to NAD(+). The decrease in absorbance, which occurs as NADH is oxidized, is measured spectrophotometrically at 340 nm on an automated chemistry analyzer.(Beutler E. Red Cell Metabolism. A Manual of Biochemical Methods. 3rd ed. Grune and Stratton; 1984:53-55; Rab MAE, van Wijk R. Enzymes of the red blood cell. In: Rifai N, Chiu RWK, Young I, Burnham CAD, Wittwer CT, eds. Tietz Textbook of Laboratory Medicine. 7th ed. Elsevier; 2023:chap 78)

PDF Report
No

Day(s) Performed
Tuesday, Thursday

Report Available
5 days

Specimen Retention Time
7 days

Performing Laboratory Location
Mayo Clinic Laboratories - Rochester Main Campus

Fees & Codes

Fees
- Authorized users can sign in to Test Prices for detailed fee information.
- Clients without access to Test Prices can contact Customer Service 24 hours a day, seven days a week.
- Prospective clients should contact their account representative. For assistance, contact Customer Service.

Test Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information
82657

LOINC® Information

Test ID	Test Order Name	Order LOINC® Value
PGKC	Phosphoglycerate Kinase, B	44053-7

Result ID	Test Result Name	Result LOINC® Value

PGKCL	Phosphoglycerate Kinase, B	44053-7